Radius Health (RDUS) Expected to Surpass Earnings Estimates: What to Know Ahead of Q1 Release

Jhe market expects Radius Health (RDUS) to post an increase in year-over-year earnings on lower revenue when it reports results for the quarter ending March 2022. This consensus outlook largely known is important in gauging the company’s earnings, but a powerful factor that could influence its course in the short term is how actual results compare to those estimates.

The stock could rise if these key numbers exceed expectations in the next earnings report, which is due out on May 5. On the other hand, if they fail, the stock could go down.

While management’s discussion of trading conditions on the earnings call will primarily determine the sustainability of the immediate price move and expectations of future earnings, it’s worth a crippling glimpse of the odds. positive surprise from BPA.

Zacks consensus estimate

This biotech company is expected to post a quarterly loss of $0.21 per share in its next report, representing a year-over-year change of +38.2%.

Revenue is expected to be $51.42 million, down 8.6% from the prior year quarter.

Trend of estimate revisions

The consensus EPS estimate for the quarter has been revised down 24.24% in the past 30 days from the current level. This essentially reflects how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of revisions to estimates by each of the covering analysts may not always be reflected in the overall change.

Price, Consensus and EPS Surprise

Revenue whisper

Estimate revisions prior to a company’s earnings release provide clues to business conditions for the period for which earnings are released. This idea is at the heart of our proprietary surprise prediction model, the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the most accurate estimate to the Zacks consensus estimate for the quarter; the most accurate estimate is a more recent version of Zacks Consensus’ EPS estimate. The idea here is that analysts revising their estimates just before the earnings release have the latest information, which could potentially be more accurate than they and other consensus contributors predicted earlier.

Thus, a positive or negative reading of the ESP on earnings theoretically indicates the likely deviation of actual earnings from the consensus estimate. However, the predictive power of the model is only significant for positive ESP readings.

A positive earnings ESP is a good predictor of an earnings beat, especially when combined with a Zacks rank of #1 (strong buy), 2 (buy), or 3 (hold). Our research shows that stocks with this combination produce a positive surprise almost 70% of the time, and a strong Zacks ranking actually increases the predictive power of Earnings ESP.

Please note that a negative ESP reading on earnings is not indicative of a shortfall. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative ESP readings on earnings and/or a Zacks rating of 4 (sell) or 5 (strong sell).

How have the numbers evolved for Radius Health?

For Radius Health, the most accurate estimate is above the Zacks consensus estimate, suggesting that analysts have recently become optimistic about the company’s earnings outlook. This translated into an ESP on revenue of +7.32%.

On the other hand, the stock currently carries a Zacks rank of No. 3.

Thus, this combination indicates that Radius Health will most likely exceed the BPA consensus estimate.

Does the history of the earnings surprise contain a clue?

When calculating estimates of a company’s future earnings, analysts often look at how closely it may have matched past consensus estimates. It is therefore worth taking a look at the surprise history to assess its influence on the number to come.

For the last reported quarter, Radius Health was expected to post a loss of $0.35 per share when it actually produced a loss of $0.33, delivering a surprise +5.71% .

Over the past four quarters, the company has beaten consensus EPS estimates three times.

Conclusion

A beat or failure in earnings may not be the only basis for a stock to move higher or lower. Many stocks end up losing ground despite declining earnings due to other factors that disappoint investors. Similarly, unexpected catalysts help a number of stocks gain despite a shortfall.

That said, betting on stocks that are expected to exceed earnings expectations increases the odds of success. That’s why it’s worth checking a company’s ESP earnings and Zacks ranking before it’s quarterly release. Be sure to use our earnings ESP filter to discover the best stocks to buy or sell before they are released.

Radius Health emerges as a compelling contender when it comes to earnings. However, investors should also pay attention to other factors to bet on this stock or walk away from it before its results are released.

Stay on top of upcoming earnings announcements with Zacks Earnings Calendar.

5 shares ready to double

Each was handpicked by a Zacks expert as the #1 preferred stock to earn +100% or more in 2021. Previous recommendations have skyrocketed +143.0%, +175.9%, + 498.3% and +673.0%.

Most of the stocks in this report fly under the radar on Wall Street, which provides a great opportunity to get in on the ground floor.

Today, check out these 5 potential home runs >>

Click to get this free report

Radius Health, Inc. (RDUS): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.